Search results for "cholesterol"

showing 10 items of 1211 documents

Oxytocin receptors and cholesterol: interaction and regulation.

2000

Cholesterol affects the ligand binding function of the oxytocin receptor in a highly specific manner. While the structurally-related cholecystokinin receptor shows a strong correlation between the membrane fluidity and its binding function, the oxytocin receptor behaves differently. A stringent and unique requirement of the affinity state of the oxytocin receptor for structural features of the sterol molecule has been found. The molecular requirements differ both from those postulated for sterol-phospholipid interactions and from those known to be necessary for the activity of other proteins. Employing a new detergent-free subcellular fractionation protocol, a two-fold enrichment of the oxy…

Models MolecularMembrane FluidityCaveolin 1Green Fluorescent ProteinsBiologyKidneyTransfectionCholecystokinin receptorCaveolinsGenes ReportermedicineMembrane fluidityExtracellularHumansReceptorCells CulturedBinding SitesCholesterol bindingCell MembraneMembrane ProteinsGeneral MedicineOxytocin receptorRecombinant ProteinsLuminescent ProteinsMembraneCholesterolOxytocinBiochemistryReceptors OxytocinBiophysicsIndicators and ReagentsReceptors CholecystokininSteroidshormones hormone substitutes and hormone antagonistsmedicine.drugExperimental physiology
researchProduct

Molecular modelling study of the role of cholesterol in the stimulation of the oxytocin receptor.

2001

Cholesterol, an integral component of membranes in Eucaryota, is a modifier of membrane properties. In vivo studies have demonstrated that cholesterol can also modulate activities of some G protein-coupled receptors (GPCRs), which are integral membrane proteins. This can result either from an effect of cholesterol on the membrane fluidity or from specific interactions of the membrane cholesterol with the receptor, as recently demonstrated for the cholecystokinin type beta (CCKRbeta) or the oxytocin receptor (OTR). Using molecular modelling, we studied conformational preferences of cholesterol and several of its analogues. Subsequently, we simulated the distributions of their preferred confo…

Models MolecularSequence Homology Amino AcidProtein ConformationMolecular Sequence DataBiologyCholecystokinin receptorOxytocin receptorGeneral Biochemistry Genetics and Molecular BiologySterolSterolsCholesterolBiochemistryReceptors OxytocinMutationBiophysicsMembrane fluidityHumansAmino Acid SequenceReceptorCholecystokininIntegral membrane proteinhormones hormone substitutes and hormone antagonistsCholecystokininG protein-coupled receptorProtein BindingActa biochimica Polonica
researchProduct

The 1.45 A resolution structure of the cryptogein-cholesterol complex: a close-up view of a sterol carrier protein (SCP) active site.

2002

Cryptogein is a small 10 kDa elicitor produced by the phytoparasitic oomycete Phytophthora cryptogea. The protein also displays a sterol carrier activity. The native protein crystallizes in space group P4(1)22, with unit-cell parameters a = b = 46.51, c = 134.9 A (diffraction limit: 2.1 A). Its complex with cholesterol crystallizes in space group C222(1), with unit-cell parameters a = 30.96, b = 94.8, c = 65.3 A and a resolution enhanced to 1.45 A. The large inner non-specific hydrophobic cavity is able to accommodate a large variety of 3-beta-hydroxy sterols. Cryptogein probably acts as a sterol shuttle helping the pathogen to grow and complete its life cycle.

Models MolecularStereochemistryMolecular Sequence DataBiologyFungal Proteinschemistry.chemical_compoundStructural BiologyAmino Acid SequenceOomyceteBinding SitesMolecular StructureSequence Homology Amino AcidCholesterolPhytophthora cryptogeaResolution (electron density)Algal ProteinsActive siteGeneral Medicinebiology.organism_classificationSterolElicitorSterolsSterol carrier proteinCholesterolBiochemistrychemistrybiology.proteinCarrier ProteinsActa crystallographica. Section D, Biological crystallography
researchProduct

Correlation of Pharmacological Properties of a Group of Hypolipaemic Drugs by Molecular Topology

1996

Abstract This investigation was undertaken to test the ability of the molecular connectivity model to predict the percentage of plasma protein binding, the percentage of total cholesterol reduction and oral LD50 in rats of a group of hypolipaemic drugs using multi-variable regression equations with multiple correlation coefficients, standard error of estimate, degrees of freedom, F-Snedecor function values, Mallow's CP and Student's t-test as criteria of fit. Regression analyses showed that the molecular connectivity model predicts these properties. Corresponding stability (cross validation) studies were made on the selected prediction models which confirmed their goodness of fit. The resul…

Molecular modelStereochemistryDegrees of freedom (statistics)Pharmaceutical ScienceModels BiologicalCross-validationLethal Dose 50CorrelationStructure-Activity RelationshipFenofibrateGoodness of fitAnimalsMultiple correlationFuransHypolipidemic AgentsPharmacologyChemistryBlood ProteinsRegressionRatsCholesterolProbucolStandard errorRegression AnalysisBiological systemProtein BindingJournal of Pharmacy and Pharmacology
researchProduct

Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patien…

2015

OBJECTIVE: To compare lipid-lowering efficacy of adding alirocumab to rosuvastatin versus other treatment strategies (NCT01730053).METHODS: Patients receiving baseline rosuvastatin regimens (10 or 20 mg) were randomized to: add-on alirocumab 75 mg every-2-weeks (Q2W) (1-mL subcutaneous injection via pre-filled pen); add-on ezetimibe 10 mg/day; or double-dose rosuvastatin. Patients had cardiovascular disease (CVD) and low-density lipoprotein cholesterol (LDL-C) ≥70 mg/dL (1.8 mmol/L) or CVD risk factors and LDL-C ≥100 mg/dL (2.6 mmol/L). In the alirocumab group, dose was blindly increased at Week 12 to 150 mg Q2W (also 1-mL volume) in patients not achieving their LDL-C target. Primary endpoi…

Monoclonal antibodymedicine.medical_specialtyTime FactorsSettore MED/09 - Medicina InternaInjections SubcutaneousHypercholesterolemiaUrology030204 cardiovascular system & hematologyPharmacologyAntibodies Monoclonal Humanizedlaw.inventionPCSK9Rosuvastatin03 medical and health sciences0302 clinical medicineDouble-Blind MethodEzetimibeRandomized controlled triallawmedicineClinical endpointHumansLow-density lipoprotein cholesterolRosuvastatinIn patient030212 general & internal medicineRosuvastatin CalciumAlirocumab; Ezetimibe; Low-density lipoprotein cholesterol; Monoclonal antibody; PCSK9; Rosuvastatin; Cardiology and Cardiovascular MedicineRetrospective StudiesAlirocumabDose-Response Relationship Drugbusiness.industryAnticholesteremic AgentsPCSK9Antibodies Monoclonalnutritional and metabolic diseasesCholesterol LDLEzetimibeRosuvastatin CalciumTreatment OutcomeCardiovascular DiseasesDrug Therapy CombinationHydroxymethylglutaryl-CoA Reductase InhibitorsbusinessCardiology and Cardiovascular MedicineFollow-Up StudiesAlirocumabmedicine.drugAtherosclerosis
researchProduct

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

2014

Item does not contain fulltext Plasma triglyceride concentration is a biomarker for circulating triglyceride-rich lipoproteins and their metabolic remnants. Common mild-to-moderate hypertriglyceridaemia is typically multigenic, and results from the cumulative burden of common and rare variants in more than 30 genes, as quantified by genetic risk scores. Rare autosomal recessive monogenic hypertriglyceridaemia can result from large-effect mutations in six different genes. Hypertriglyceridaemia is exacerbated by non-genetic factors. On the basis of recent genetic data, we redefine the disorder into two states: severe (triglyceride concentration >10 mmol/L), which is more likely to have a mono…

Multifactorial InheritanceSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Genome-wide association studyDisease030204 cardiovascular system & hematologyISCHEMIC-HEART-DISEASEBioinformaticshypertriglyceridaemia0302 clinical medicineEndocrinologyGENERAL-POPULATIONHypertriglyceridemiatreatmentmedicine.diagnostic_testREMNANT CHOLESTEROLCombined Modality Therapy3. Good healthLIPASE DEFICIENCYdiagnosiPLASMA TRIGLYCERIDESDENSITY-LIPOPROTEIN CHOLESTEROLCARDIOVASCULAR-DISEASEPractice Guidelines as TopicBiomarker (medicine)Multifactorial Inheritancemedicine.medical_specialty030209 endocrinology & metabolismHealth PromotionArticle03 medical and health sciencesPharmacotherapyInternal medicineInternal MedicinemedicineAnimalsHumansHOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIAGenetic Predisposition to DiseaseAlleleGENOME-WIDE ASSOCIATIONLife Stylehypertriglyceridaemia; diagnosis; treatmentTriglyceridesGenetic testingbusiness.industryHypertriglyceridemianutritional and metabolic diseasesmedicine.diseaseEndocrinologyNONFASTING TRIGLYCERIDESbusinessBiomarkersThe lancet. Diabetesendocrinology
researchProduct

Regulation of cholesterol metabolism in the retina under experimental conditions associated with glaucoma

2019

Cholesterol is a lipid found in every animal cell and is necessary for its survival. Among its multiple roles in the body, it is a component of cell membranes that is crucial for the maintenance of their structure and fluidity and is thus implicated in the modulation of many signalling pathways. Neurons are especially dependant on cholesterol input since the proper composition of their plasma membrane is required for vesicular exocytosis of neurotransmitters and transduction of the post-synaptic signal. It has been shown that both an excess and a lack of cholesterol is neurotoxic. Moreover, many neurodegenerative diseases, such as Alzheimer’s or Huntington’s disease, have been associated wi…

Müller cellsInflammation24(S)-Hydroxycholesterol24(S)-HydroxycholestérolGlioseCellules de MüllerLaser photocoagulationGliosisHyperpression oculaireOcular hypertensionPhotocoagulation laser[SDV.BBM.BC] Life Sciences [q-bio]/Biochemistry Molecular Biology/Biochemistry [q-bio.BM][SDV.BBM.BC]Life Sciences [q-bio]/Biochemistry Molecular Biology/Biomolecules [q-bio.BM]
researchProduct

Phytochemical indicaxanthin suppresses 7-ketocholesterol-induced THP-1 cell apoptosis by preventing cytosolic Ca++ increase and oxidative stress

2013

7-Ketocholesterol (7-KC)-induced apoptosis of macrophages is considered a key event in the development of human atheromas. In the present study, the effect of indicaxanthin (Ind), a bioactive pigment from cactus pear fruit, on 7-KC-induced apoptosis of human monocyte/macrophage THP-1 cells was investigated. A pathophysiological condition was simulated by using amounts of 7-KC that can be reached in human atheromatous plaque. Ind was assayed within a micromolar concentration range, consistent with its plasma level after dietary supplementation with cactus pear fruit. Pro-apoptotic effects of 7-KC were assessed by cell cycle arrest, exposure of phosphatidylserine at the plasma membrane, varia…

NADPH oxidase-4MacrophageSettore BIO/10 - BiochimicaApoptosiIndicaxanthin7-Ketocholesterol
researchProduct

Protective effect of antioxidants contained in milk-based fruit beverages against sterol oxidation products

2017

Abstract Sterol oxidation products (SOPs) have shown cytotoxic effect in human intestinal cells; however, their effect within a food matrix has not been assayed yet. This study evaluated the possible cytotoxic effect of SOPs within bioaccessible fractions (BFs) of two milk-based fruit beverages with (BFA)/without (BFB) plant sterols in differentiated Caco-2 cells and if the BFs counteracted the cytotoxic effect induced by COPs mixture (30 and 60 μM). BFs did not evoke cytotoxic effect in any of the tests carried out and they protected against the loss of intestinal cohesion, mitochondrial depolarization and necrosis induced by COPs mixture. Moreover, BFB sample protected from cell cycle arr…

NecrosisCell cycle checkpointCytotoxic effectCholesterol oxidation productsMedicine (miscellaneous)Milk-based fruit beverage0404 agricultural biotechnologymedicineCytotoxic T cellTX341-641Bioaccessible fractionsCaco-2 cellsOverproductionNutrition and DieteticsNutrition. Foods and food supplyChemistryPhytosterol oxidation products04 agricultural and veterinary sciences040401 food scienceIntestinal epitheliumSterolBiochemistryCaco-2medicine.symptomPlant sterolsFood ScienceJournal of Functional Foods
researchProduct

Short-term atorvastatin treatment does not modify neointimal morphology but reduces MMP-2 expression in normocholesterolemic rabbit stented arteries.

2006

The aim of our study was to explore some potential pleiotropic effects of atorvastatin, after stenting in the iliac arteries of normocholesterolemic rabbits. On day 0, 27 rabbits underwent stent implantation and were randomized into either the control group (standard chow, CTRL, n = 15) or the atorvastatin group (10 mg/kg/d per os, Ator, n = 12). On day 30, the stented arteries were harvested for histomorphometry and neointimal analysis [macrophages, matrix metalloproteinases (MMP-2), tissue inhibitor of metalloproteinase-2, vascular smooth muscle cells, and collagen]. Atorvastatin did not induce significant histomorphometric and inflammatory modifications but reduced neointimal expression …

NeointimaMalemedicine.medical_specialtyStatinVascular smooth musclemedicine.drug_classAtorvastatinHypercholesterolemiaUrologyMatrix metalloproteinaseIliac ArteryMuscle Smooth VascularRestenosisInternal medicinemedicineAtorvastatinAnimalsPyrrolesPharmacologyTissue Inhibitor of Metalloproteinase-2Cellular densityChemistrymedicine.diseaseImmunohistochemistryHeptanoic AcidsCardiologyMatrix Metalloproteinase 2StentsStatin therapyRabbitsHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicineTunica Intimamedicine.drugJournal of cardiovascular pharmacology
researchProduct